Xeris Biopharma (NASDAQ:XERS) insider Kevin Mcculloch sells 15,000 shares of stock. August 4, 2026 Key points. * Insider sale: Kevin Mcculloch sold 15,000 Xeris Biopharma shares at an average of $8.02 for $120,300 under a pre-arranged Rule 10b5-1 plan, reducing his position by 0.89% to 1,676,126 shares. * Stock performance: Xeris shares traded at $8.19, with the stock up from its 50-day average of $7.55 and 200-day average of $6.78. The company has a $1.41 billion market capitalization and a 52-week range of $5.25 to $10.08. * Analyst outlook: Analysts give Xeris a consensus "Moderate Buy" rating with an average price target of $10.80; the company recently reported quarterly revenue of $83.13 million and EPS of $0.01. * Five stocks we like better than Xeris Biopharma. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin Mcculloch sold 15,000 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total value of $120,300.00. Following the sale, the insider owned 1,676,126 shares of the company's stock, valued at approximately $13,442,530.52. This represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Kevin Mcculloch also recently made the following trade(s): * On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.03, for a total value of $722,700.00. Xeris Biopharma stock performance. NASDAQ:XERS traded up $0.06 during mid-day trading on Tuesday, hitting $8.19. 1,838,477 shares of the stock were exchanged, compared to its average volume of 1,872,077. The firm's 50-day simple moving average is $7.55 and its 200 day simple moving average is $6.78. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of 136.50 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. As a group, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year. Institutional investors weigh in on Xeris Biopharma. Several institutional investors have recently made changes to their positions in the stock. Apella Capital LLC increased its stake in Xeris Biopharma by 2,359.0% during the 4th quarter. Apella Capital LLC now owns 245,897 shares of the company's stock worth $1,930,000 after acquiring an additional 235,897 shares during the period. Rice Hall James & Associates LLC bought a new stake in shares of Xeris Biopharma during the 1st quarter valued at $1,456,000. Vanguard Group Inc. grew its holdings in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company's stock worth $87,815,000 after purchasing an additional 1,358,760 shares in the last quarter. Granahan Investment Management LLC grew its holdings in shares of Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company's stock worth $9,604,000 after purchasing an additional 873,236 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new position in shares of Xeris Biopharma in the first quarter worth $1,204,000. 42.75% of the stock is currently owned by institutional investors. Analyst upgrades and downgrades. Separately, Weiss Ratings upgraded shares of Xeris Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $10.80. Xeris Biopharma company profile. Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas. The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Xeris Biopharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list. While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Xeris appoints CEO John Shannon as board chair, adds Nerissa Kreher to board. June 30, 2026 John Shannon Xeris Biopharma Holdings has named Chief Executive Officer John Shannon as chairman of its board of directors and appointed biotechnology executive Nerissa Kreher, M.D., to the board as the company continues expanding its commercial portfolio and advancing its late-stage pipeline. The leadership changes take effect July 1, 2026. Shannon succeeds Marla Persky as board chair, while Persky will continue serving as a director in the newly designated role of lead independent director. The appointment of Kreher expands the Chicago-based biopharmaceutical company's board to eight members. The governance changes come after more than two years of Shannon leading Xeris as CEO, during which the company has continued to grow its commercial business while advancing product development across endocrine and rare disease therapies. "When John was appointed CEO, the Board wanted him to focus on strategy and growth. Over the past two years, John clearly demonstrated the leadership and vision necessary to advance Xeris' strategy and achieve the company's objectives," Persky said. "His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman." Shannon said he looks forward to continuing to guide the company's strategic direction in the expanded role while working with management to build on Xeris' commercial and development initiatives. "I am honored to have been named chairman of Xeris," Shannon said. "Working alongside our dedicated leadership team and talented workforce, I remain confident in the continued rapid growth of our commercial portfolio, the advancement of our late-stage pipeline, and the strength of our balance sheet. I believe strongly in the future of this company and in our ability to deliver long-term value to shareholders." He also thanked Persky for her leadership as board chair, noting that the company will continue to benefit from her experience as lead independent director. The company also strengthened its board with the addition of Kreher, a physician-scientist and biotechnology executive with more than 20 years of experience leading clinical development and commercialization programs for rare disease therapies. Kreher currently serves as chief medical officer of Alltrna, where she oversees clinical development, regulatory affairs and patient advocacy efforts, including the company's transition into clinical-stage development. Her previous leadership roles include chief medical officer positions at Entrada Therapeutics, Tiburio Therapeutics and AVROBIO, as well as senior clinical and medical affairs positions at Zafgen, Shire and Enobia Pharma. In addition to her executive responsibilities, Kreher serves as an independent director at Rezolute Bio. She earned her medical degree from East Carolina University School of Medicine, a master's degree in clinical research from Indiana University and an Executive MBA from Northeastern University. "We are pleased to welcome Dr. Nerissa Kreher to our Board of Directors," Shannon said. "An accomplished physician-scientist, biotech executive and pediatric endocrinologist, Nerissa has been instrumental in the development and commercialization of therapies for rare diseases across therapeutic areas, including neuromuscular, endocrinology and metabolic disorders. I am confident that Nerissa will be a tremendous asset to the company." Xeris develops and commercializes therapies for endocrine and rare diseases. Its commercial portfolio includes Recorlev(R) for endogenous Cushing's syndrome, Gvoke(R) for severe hypoglycemia and Keveyis(R) for primary periodic paralysis. The company's development pipeline is led by XP-8121, a Phase 3-ready, once-weekly subcutaneous treatment for hypothyroidism, along with multiple early-stage programs built on its proprietary XeriSol(R) and XeriJect(R) drug formulation platforms.

Xeris Biopharma Holdings has appointed CEO John Shannon as Chair of the Board, effective 1 July 2026. Shannon succeeds Marla Persky, who will remain on the board as Lead Independent Director. The biopharmaceutical company also appointed Dr Nerissa Kreher to its board, expanding it to eight members. Dr Kreher currently serves as Chief Medical Officer at Alltrna and brings over two decades of experience in rare disease development and commercialisation across neuromuscular, endocrinology and metabolic disorders. Xeris commercialises three products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycaemia, and Keveyis for primary periodic paralysis. The company's pipeline is led by XP-8121, a Phase 3-ready weekly injection for hypothyroidism.